Home LiteratureArticle Details
PMID: 25247240 Published · epublish English Journal Article Review

Mir-34: a new weapon against cancer?

Molecular therapy. Nucleic acids ·Vol. 3 ·2014-09-23 ·Pages e194

Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M

Abstract

The microRNA(miRNA)-34a is a key regulator of tumor suppression. It controls the expression of a plethora of target proteins involved in cell cycle, differentiation and apoptosis, and antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. In this review, we focus on the molecular mechanisms of miR-34a-mediated tumor suppression, giving emphasis on the main miR-34a targets, as well as on the principal regulators involved in the modulation of this miRNA. Moreover, we shed light on the miR-34a role in modulating responsiveness to chemotherapy and on the phytonutrients-mediated regulation of miR-34a expression and activity in cancer cells. Given the broad anti-oncogenic activity of miR-34a, we also discuss the substantial benefits of a new therapeutic concept based on nanotechnology delivery of miRNA mimics. In fact, the replacement of oncosuppressor miRNAs provides an effective strategy against tumor heterogeneity and the selective RNA-based delivery systems seems to be an excellent platform for a safe and effective targeting of the tumor.

Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Misso Gabriella
Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
Di Martino Maria Teresa
Department of Experimental and Clinical Medicine, Magna Graecia University and Medical OncologyUnit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy.
De Rosa Giuseppe
Department of Pharmacy, University "Federico II" of Naples, Naples, Italy.
Farooqi Ammad Ahmad
Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College, Lahore, Pakistan.
Lombardi Angela
Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
Campani Virginia
Department of Pharmacy, University "Federico II" of Naples, Naples, Italy.
Zarone Mayra Rachele
Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
Gullà Annamaria
Department of Experimental and Clinical Medicine, Magna Graecia University and Medical OncologyUnit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy.
Tagliaferri Pierosandro
Department of Experimental and Clinical Medicine, Magna Graecia University and Medical OncologyUnit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy.
Tassone Pierfrancesco
1] Department of Experimental and Clinical Medicine, Magna Graecia University and Medical OncologyUnit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy [2] Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA.
Caraglia Michele
1] Department of Experimental and Clinical Medicine, Magna Graecia University and Medical OncologyUnit, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy [2] Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA.
References (150)
150 references, click to expand
  1. Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR.
    PLoS One. 2013 Aug 01;8(8):e70372 PMID: 23936419
  2. Clinical implications of microRNAs in cancer.
    Biotech Histochem. 2013 Oct;88(7):388-96 PMID: 23647010
  3. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.
    PLoS One. 2014 Feb 27;9(2):e90005 PMID: 24587182
  4. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
    Cell Death Dis. 2012 Nov 29;3:e436 PMID: 23190608
  5. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Breast Cancer Res Treat. 2011 Nov;130(2):663-79 PMID: 21814748
  6. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
    J Control Release. 2000 Mar 1;65(1-2):271-84 PMID: 10699287
  7. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.
    PLoS One. 2014 Mar 12;9(3):e91546 PMID: 24621885
  8. Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells.
    Oncol Rep. 2013 Jun;29(6):2169-74 PMID: 23525472
  9. Targeting microRNAs in cancer: rationale, strategies and challenges.
    Nat Rev Drug Discov. 2010 Oct;9(10):775-89 PMID: 20885409
  10. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
    Nat Med. 2011 Feb;17(2):211-5 PMID: 21240262
  11. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
    Cancer Biother Radiopharm. 2013 Feb;28(1):45-50 PMID: 23036084
  12. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.
    Brain Res. 2012 May 15;1454:1-13 PMID: 22498172
  13. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1.
    Blood. 2011 Jun 9;117(23):6227-36 PMID: 21460242
  14. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
    Clin Cancer Res. 2012 Nov 15;18(22):6260-70 PMID: 23035210
  15. The miR-34 family in cancer and apoptosis.
    Cell Death Differ. 2010 Feb;17(2):193-9 PMID: 19461653
  16. Promises and challenges of MicroRNA-based treatment of multiple myeloma.
    Curr Cancer Drug Targets. 2012 Sep;12(7):838-46 PMID: 22671926
  17. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
    J Cell Physiol. 2014 Dec;229(12):2106-16 PMID: 24819167
  18. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a.
    Mol Cell Biochem. 2013 Oct;382(1-2):103-11 PMID: 23771315
  19. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
    Leukemia. 2013 Feb;27(2):353-61 PMID: 22810507
  20. A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH.
    Biochem Biophys Res Commun. 2012 Feb 24;418(4):682-8 PMID: 22301190
  21. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Carcinogenesis. 2009 Nov;30(11):1903-9 PMID: 19736307
  22. miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis.
    PLoS One. 2012;7(3):e33844 PMID: 22479456
  23. Reduced levels of miR-34a in neuroblastoma are not caused by mutations in the TP53 binding site.
    Genes Chromosomes Cancer. 2009 Jul;48(7):539-43 PMID: 19373781
  24. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
    Cancer Res. 2009 Oct 1;69(19):7569-76 PMID: 19773441
  25. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.
    PLoS One. 2012;7(8):e42034 PMID: 22870278
  26. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells.
    Cell Stem Cell. 2013 May 2;12(5):602-15 PMID: 23642368
  27. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.
    Clin Exp Med. 2013 May;13(2):109-17 PMID: 22623155
  28. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.
    Cancer Res. 2008 Jun 1;68(11):4123-32 PMID: 18519671
  29. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer.
    Clin Cancer Res. 2013 Feb 1;19(3):710-20 PMID: 23243217
  30. MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.
    PLoS One. 2013 Jun 21;8(6):e67581 PMID: 23805317
  31. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma.
    Cancer Cell. 2012 Sep 11;22(3):291-303 PMID: 22975373
  32. MicroRNAs and cancer; an overview.
    Curr Pharm Biotechnol. 2014;15(5):430-7 PMID: 24846068
  33. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response.
    J Immunol. 2010 Mar 1;184(5):2369-76 PMID: 20130213
  34. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo.
    PLoS One. 2012;7(3):e33778 PMID: 22457788
  35. Genomic analysis of microRNA time-course expression in liver of mice treated with genotoxic carcinogen N-ethyl-N-nitrosourea.
    BMC Genomics. 2010 Oct 28;11:609 PMID: 21029445
  36. The therapeutic potential of microRNAs in cancer.
    Cancer J. 2012 May-Jun;18(3):275-84 PMID: 22647365
  37. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
    Cancer Res. 2014 Feb 15;74(4):1261-1271 PMID: 24371224
  38. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Biomaterials. 2014 May;35(14):4333-44 PMID: 24565525
  39. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion.
    Mol Ther. 2012 Dec;20(12):2326-34 PMID: 23032974
  40. miR-221 overexpression contributes to liver tumorigenesis.
    Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9 PMID: 20018759
  41. MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression.
    Int J Med Sci. 2013;10(6):676-82 PMID: 23569431
  42. miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis.
    Cancer Sci. 2012 Sep;103(9):1737-43 PMID: 22624980
  43. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.
    Mol Ther. 2010 Sep;18(9):1650-6 PMID: 20606648
  44. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.
    Int J Cancer. 2012 Jun 1;130(11):2526-38 PMID: 21702042
  45. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis.
    PLoS One. 2012;7(5):e37601 PMID: 22629428
  46. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation.
    Biochim Biophys Acta. 2014 Jan;1845(1):42-52 PMID: 24295567
  47. miR-34a sets the "sweet spot" for notch in colorectal cancer stem cells.
    Cell Stem Cell. 2013 May 2;12(5):499-501 PMID: 23642356
  48. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression.
    J Clin Invest. 2012 Sep;122(9):3170-83 PMID: 22850877
  49. A microRNA expression signature of human solid tumors defines cancer gene targets.
    Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 PMID: 16461460
  50. In-depth analysis shows synergy between erlotinib and miR-34a.
    PLoS One. 2014 Feb 14;9(2):e89105 PMID: 24551227
  51. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.
    PLoS One. 2012;7(5):e38129 PMID: 22662276
  52. Oncomirs - microRNAs with a role in cancer.
    Nat Rev Cancer. 2006 Apr;6(4):259-69 PMID: 16557279
  53. Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model.
    J Mol Med (Berl). 2013 Jun;91(6):715-25 PMID: 23292172
  54. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.
    J Biol Chem. 2013 Sep 20;288(38):27343-27357 PMID: 23902763
  55. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.
    Oncotarget. 2012 Oct;3(10):1246-58 PMID: 23100393
  56. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model.
    Biomaterials. 2013 Mar;34(9):2265-76 PMID: 23298779
  57. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
    Technol Cancer Res Treat. 2014 Feb;13(1):77-86 PMID: 23862748
  58. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
    J Pathol. 2012 Apr;226(5):796-805 PMID: 21960059
  59. Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.
    Biomed Res Int. 2014;2014:217365 PMID: 24683542
  60. CD95 is part of a let-7/p53/miR-34 regulatory network.
    PLoS One. 2012;7(11):e49636 PMID: 23166734
  61. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.
    Curr Pharm Biotechnol. 2014;15(5):459-67 PMID: 24846067
  62. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.
    Leukemia. 2011 Apr;25(4):707-11 PMID: 21233838
  63. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
    Clin Cancer Res. 2013 Jun 15;19(12):3130-42 PMID: 23613318
  64. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin.
    Med Oncol. 2012 Dec;29(4):2473-80 PMID: 22246523
  65. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.
    Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 PMID: 17875987
  66. The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs.
    RNA Biol. 2011 Sep-Oct;8(5):817-28 PMID: 21881409
  67. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
    J Cell Physiol. 2013 Jul;228(7):1506-15 PMID: 23254643
  68. MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells.
    Radiat Oncol. 2013 Oct 05;8:231 PMID: 24094113
  69. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells.
    Cancer Lett. 2011 Jan 28;300(2):197-204 PMID: 21067862
  70. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.
    PLoS One. 2011;6(11):e26122 PMID: 22102859
  71. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Cancer Res. 2012 Nov 1;72(21):5576-87 PMID: 22964582
  72. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells.
    Carcinogenesis. 2010 Jun;31(6):1037-44 PMID: 20351093
  73. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
    Biotechnol Adv. 2012 Jan-Feb;30(1):169-84 PMID: 21871555
  74. MicroRNAs and other non-coding RNAs as targets for anticancer drug development.
    Nat Rev Drug Discov. 2013 Nov;12(11):847-65 PMID: 24172333
  75. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
    Cancer Res. 2012 Jan 15;72(2):460-71 PMID: 22102694
  76. Aberrant microRNA expression in multiple myeloma.
    Eur J Haematol. 2013 Aug;91(2):95-105 PMID: 23586898
  77. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.
    Cell Cycle. 2010 Mar 15;9(6):1031-6 PMID: 20190569
  78. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
    Leukemia. 2009 Mar;23(3):625-7 PMID: 18818704
  79. DNA methylation and microRNA dysregulation in cancer.
    Mol Oncol. 2012 Dec;6(6):567-78 PMID: 22902148
  80. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.
    Curr Cancer Drug Targets. 2012 Sep;12(7):814-22 PMID: 22671927
  81. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.
    J Clin Invest. 2014 Apr;124(4):1853-67 PMID: 24642471
  82. miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells.
    Tumour Biol. 2014 Feb;35(2):1503-10 PMID: 24078448
  83. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.
    Clin Cancer Res. 2014 Aug 1;20(15):4141-53 PMID: 24916701
  84. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells.
    Blood. 2014 Jun 5;123(23):3622-34 PMID: 24755409
  85. Impaired DICER1 function promotes stemness and metastasis in colon cancer.
    Oncogene. 2014 Jul 24;33(30):4003-15 PMID: 24096488
  86. miR-34a is essential for p19(Arf)-driven cell cycle arrest.
    Cell Cycle. 2014;13(5):792-800 PMID: 24401748
  87. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.
    Oncotarget. 2013 Sep;4(9):1399-415 PMID: 24009080
  88. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
    Adv Healthc Mater. 2015 Jan 28;4(2):281-90 PMID: 25044638
  89. The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression.
    PLoS One. 2013 Sep 03;8(9):e73195 PMID: 24019906
  90. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
    Clin Cancer Res. 2013 Apr 15;19(8):2096-106 PMID: 23446999
  91. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET.
    PLoS One. 2013 Apr 10;8(4):e61054 PMID: 23593387
  92. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
    Curr Drug Targets. 2013 Sep;14(10):1144-9 PMID: 23834146
  93. Differential expression of microRNAs during hepatocarcinogenesis induced by methyl deficiency in rats.
    Nutr Rev. 2008 Aug;66 Suppl 1:S33-5 PMID: 18673486
  94. MicroRNA expression profiles classify human cancers.
    Nature. 2005 Jun 9;435(7043):834-8 PMID: 15944708
  95. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line.
    DNA Cell Biol. 2013 Dec;32(12):699-707 PMID: 24050776
  96. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.
    Mol Ther. 2011 Jun;19(6):1116-22 PMID: 21427705
  97. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
    PLoS One. 2011;6(8):e24099 PMID: 21909380
  98. Maturation of microRNA is hormonally regulated by a nuclear receptor.
    Mol Cell. 2009 Oct 23;36(2):340-7 PMID: 19854141
  99. Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor.
    Cancer Sci. 2012 Dec;103(12):2139-43 PMID: 22957647
  100. Circulating miR-34a levels are reduced in colorectal cancer.
    J Surg Oncol. 2012 Dec;106(8):947-52 PMID: 22648208
  101. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 PMID: 12434020
  102. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.
    Cell Cycle. 2013 Dec 1;12(23):3650-62 PMID: 24091729
  103. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.
    Genes Dev. 2014 Mar 1;28(5):438-50 PMID: 24532687
  104. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
    Prostate. 2010 Oct 1;70(14):1501-12 PMID: 20687223
  105. Recent developments in nanoparticle-based siRNA delivery for cancer therapy.
    Biomed Res Int. 2013;2013:782041 PMID: 23844368
  106. Oligonucleotide delivery in cancer therapy.
    Expert Opin Drug Deliv. 2010 Nov;7(11):1263-78 PMID: 20977291
  107. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.
    Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S125-37 PMID: 23692413
  108. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis.
    Breast Cancer Res. 2012 May 22;14(3):R80 PMID: 22616882
  109. miR-34 - a microRNA replacement therapy is headed to the clinic.
    Front Genet. 2012 Jul 02;3:120 PMID: 22783274
  110. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
    Oncotarget. 2013 Feb;4(2):242-55 PMID: 23479461
  111. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.
    Cell. 2009 Jun 12;137(6):1005-17 PMID: 19524505
  112. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions.
    Cell Cycle. 2011 Dec 15;10(24):4256-71 PMID: 22134354
  113. SMAD proteins control DROSHA-mediated microRNA maturation.
    Nature. 2008 Jul 3;454(7200):56-61 PMID: 18548003
  114. Frequent downregulation of miR-34 family in human ovarian cancers.
    Clin Cancer Res. 2010 Feb 15;16(4):1119-28 PMID: 20145172
  115. Active targeting strategies for anticancer drug nanocarriers.
    Curr Drug Deliv. 2012 May;9(3):255-68 PMID: 22452402
  116. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.
    Med Oncol. 2013 Mar;30(1):413 PMID: 23292869
  117. Causes and consequences of microRNA dysregulation in cancer.
    Nat Rev Genet. 2009 Oct;10(10):704-14 PMID: 19763153
  118. MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation.
    PLoS One. 2013 Aug 26;8(8):e72383 PMID: 23991105
  119. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.
    J Cell Physiol. 2014 Jan;229(1):97-9 PMID: 23794259
  120. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.
    Tumour Biol. 2014 Feb;35(2):1287-95 PMID: 24068565
  121. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF.
    J Hematol Oncol. 2012 Sep 19;5:58 PMID: 22992310
  122. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
    Cancer Discov. 2013 Apr;3(4):406-17 PMID: 23358650
  123. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells.
    Curr Drug Targets. 2012 Dec;13(14):1750-6 PMID: 23140286
  124. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas.
    J Cell Biochem. 2006 Oct 15;99(3):671-8 PMID: 16924677
  125. MiR-34, SIRT1 and p53: the feedback loop.
    Cell Cycle. 2009 Mar 1;8(5):712-5 PMID: 19221490
  126. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.).
    Mol Ther. 2013 Sep;21(9):1678-86 PMID: 23836017
  127. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.
    Curr Pharm Biotechnol. 2014;15(5):475-85 PMID: 24846062
  128. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma.
    PLoS One. 2011;6(9):e24584 PMID: 21931765
  129. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells.
    Int J Cancer. 2012 Dec 1;131(11):2668-77 PMID: 22438124
  130. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis.
    Mol Cell Proteomics. 2011 Aug;10(8):M111.010462 PMID: 21566225
  131. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
    Oncogene. 2013 Feb 28;32(9):1155-63 PMID: 22580610
  132. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.
    Oncotarget. 2014 May 30;5(10):3039-54 PMID: 24839982
  133. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice.
    Mol Cancer Ther. 2011 Aug;10(8):1470-80 PMID: 21622730
  134. CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a.
    PLoS One. 2013;8(3):e59563 PMID: 23533633
  135. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway.
    J Radiat Res. 2013 Jul 1;54(4):611-9 PMID: 23349340
  136. MicroRNA signatures in human cancers.
    Nat Rev Cancer. 2006 Nov;6(11):857-66 PMID: 17060945
  137. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells.
    Cancer Lett. 2009 Mar 8;275(1):44-53 PMID: 19006648
  138. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.
    Arch Med Res. 2012 Oct;43(7):514-21 PMID: 23085450
  139. Creating a flexible multiple microRNA expression vector by linking precursor microRNAs.
    Biochem Biophys Res Commun. 2011 Jul 29;411(2):276-80 PMID: 21726537
  140. Early targets of miR-34a in neuroblastoma.
    Mol Cell Proteomics. 2014 Aug;13(8):2114-31 PMID: 24912852
  141. microRNA-34a promotes DNA damage and mitotic catastrophe.
    Cell Cycle. 2013 Nov 15;12(22):3500-11 PMID: 24091633
  142. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
    Oncogene. 2011 Jun 23;30(25):2888-99 PMID: 21317930
  143. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.
    Cell Cycle. 2008 Aug 15;7(16):2591-600 PMID: 18719384
  144. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
    Cancer Res. 2010 Jul 15;70(14):5923-30 PMID: 20570894
  145. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells.
    PLoS One. 2012;7(1):e29722 PMID: 22235332
  146. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.
    Am J Transl Res. 2012;4(4):432-42 PMID: 23145211
  147. Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells.
    Neurochem Res. 2013 Feb;38(2):420-32 PMID: 23192662
  148. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
    Clin Chem. 2013 Oct;59(10):1489-96 PMID: 23748853
  149. Toxicity of cationic lipids and cationic polymers in gene delivery.
    J Control Release. 2006 Aug 10;114(1):100-9 PMID: 16831482
  150. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.
    Ann Surg. 2007 Aug;246(2):259-68 PMID: 17667505
Article Info
Journal
Molecular therapy. Nucleic acids
Abbr.
Mol Ther Nucleic Acids
ISSN
2162-2531
DOI
10.1038/mtna.2014.47
Published
2014-09-23
Epub
2014-00-23
Pages
e194
Language
English
Region
United States
NLM ID
101581621
PMCID
PMC4222652
External Links
PubMed source DOI: 10.1038/mtna.2014.47 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2